IRD

3.9902.21%
BR

Benjamin R. Yerxa

President & Director

Dr. Benjamin R. Yerxa, also known as Ben, Ph.D., is President and Director of Opus Genetics, Inc. from October 2024 and was its Chief Executive Officer since June 2022 until 2024 and serves as its Founder. He served as Director at Atsena Therapeutics, Inc. He served as Chief Executive Officer of Foundation Fighting Blindness from 2017 to July 2022 and Member of Clinical & Scientific Advisory Board Member. He previously served as Acting CEO of Opus. He served as Chief Executive Officer of Foundation Fighting Blindness and the Retinal Degeneration Fund since October 2018 until July 2022. He has been an Independent Director at Clearside Biomedical, Inc. since March 02, 2022. He serves on the Board of Directors of the North Carolina Biotechnology Center since 2008 and several private ophthalmic companies like Parion Sciences. He served as Director of SparingVision SAS until 2022. Prior to joining the Foundation, Dr. Yerxa served as the Chief Scientific Officer of Envisia Therapeutics Inc. and had been its President since March 2015. Dr. Yerxa serves as Director of Nacuity Pharmaceuticals, Inc. since 2019. Dr. Yerxa Co-founded Envisia Therapeutics Inc. Dr. Yerxa has served in senior leadership roles in multiple public and private ophthalmology companies and has been involved with the discovery and development of numerous Investigational New Drug Applications, Phase 3 clinical programs, New Drug Applications, drug approvals and product launches. Dr. Yerxa had been Chief Scientific Officer of Liquidia Technologies, Inc. since August 28, 2012 until 2015. Dr. Yerxa is a founding officer of Envisia. Dr. Yerxa served as Vice President of Research and Development at Clearside BioMedical, Inc. from 2011 until 2012. Dr. Yerxa was Consultant of Inspire Pharmaceuticals, Inc. from August 2010 to December 2010. Dr. Yerxa served as Chief of Research & Development and Executive Vice President of Inspire Pharmaceuticals, Inc. since September 1, 2008 and served as its Chief Scientific Officer since February 20, 2007 to September 2008. Dr. Yerxa served as an Executive Vice President of Strategic Operations for Inspire Pharmaceuticals, Inc. from February 20, 2007 to September 1, 2008. Dr. Yerxa served as Chief of Scientific Operations & Alliances of Inspire Pharmaceuticals Inc. from December 2005 to February 20, 2007 and as its Senior Vice President, Discovery from March 2003 to February 20, 2007. Dr. Yerxa has pharmaceutical/biotechnology experience, including experience in the ophthalmology, pulmonary, cardiovascular and HIV fields from drug discovery through product launches. He has been involved with the discovery and development of nine INDs, four Phase III clinical programs, two NDAs and two drug approvals. He served 10 years as a Section 16 officer reporting to the Chief Executive Officer of a top-50 public biotech company (Inspire) from IPO through multiple follow-on financings. He is an entrepreneur with more than 50 issued US patents and was involved with the creation of the ophthalmic commercial infrastructure and the launch of ELESTAT and AZASITE. He supervised drug discovery, clinical, preclinical, regulatory, drug safety and biostatistics functions. He has also supervised business development, manufacturing and technical operations groups. Dr. Yerxa joined Inspire Pharmaceuticals Inc. in August 1995 as Senior Research Chemist and previously served several positions, including Vice President of Discovery from February 2000 to March 2003 and Senior Director of Preclinical Programs. He supervised the molecular pharmacology, chemistry, pre-clinical and intellectual property teams. He created a new strategic opportunity for Inspire Pharmaceuticals Inc. by developing the concept of ophthalmic uses for Inspire Pharmaceuticals Inc.'s core P2Y2 technology. He served as Senior Director of Preclinical Programs since December 1999, Dr. Yerxa served as Director of Preclinical Programs. While in chemistry, he served as the Preclinical Project Leader for INS365. He is a Senior Research Chemist and focused on designing and synthesizing new P2Y receptor agonists. From October 1993 to August 1995, he was a Research Scientist at Burroughs Wellcome Co. Dr. Yerxa worked at Biophysica, Inc. for over two years, synthesizing radiocontrast agents. He developed scale-up procedures for the industrial production of Oxilan®, a marketed imaging product. He served as Co-Chairman of Scientific Advisory Board Inspire Pharmaceuticals Inc. since June 2000. He received the Southeastern Region American Chemical Society (ACS) Industrial Innovation Award for discoveries related to his work with P2Y2receptors and was instrumental in developing the concept of ophthalmic uses for Inspire's core P2Y2receptor technology. Dr. Yerxa is a named inventor on 44 of Inspire's total of more than 65 issued U.S. patents. Dr. Yerxa received the Triangle Business Journal's 40 under 40 award, recognizing his contributions in business and leadership. He was also a finalist for Ernst & Young's Entrepreneur of the Year in NC 2003. He is on the board of Trefoil Therapeutics since 2026, Sharefish, Inc. since 2009. He was Vice President of Product Development, Parion Sciences, Inc., a private biopharmaceutical company from 2010 until 2011. Dr. Yerxa has a B.A. in Chemistry from the University of California, San Diego and a Ph.D. in Organic Chemistry from the University of California, Irvine.

Positions